Anavex names Michael Gold to advisory board
This article was originally published in Scrip
New York-based Anavex, which develops novel drugs for Alzheimer's, CNS diseases and various types of cancer has named Dr Michael Gold to its scientific advisory board. Dr Gold currently serves as vice-president of CMS practice at biopharmaceutical firm UCB. His background also includes leadership roles at GlaxoSmithKline, Johnson & Johnson and Bristol-Myers Squibb.